Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Non-Partisan Lawmaker Group on Cooperation with WHO Set Up, Eyeing Asia Pacific Region Congress in Japan this Summer
April 26, 2017
- Me-Too Drugs in Jeopardy? CEFP Working Group Pushes Rigid Drug Selection for Innovation Premium
April 26, 2017
- LDP Health Panel to Compile Resolution on Drug Pricing
April 25, 2017
- Drug Pricing Is Internal Affairs Not Subject to Bilateral Talks: Minister
April 25, 2017
- Apply GDP to Cash-and-Carry Dealers Too: MHLW Panel Members
April 24, 2017
- MHLW Committee Backs Approval of Mundipharma’s PTCL Med Pralatrexate
April 24, 2017
- Commerce Secretary Ross Made No Specific Demand on Drug Pricing: Shiozaki
April 24, 2017
- Negative Opinions Exist for Use of Cost Effective Assessments in Drug Listing: MHLW Official
April 24, 2017
- Sakigake Fast-Track Designation Given to Aducanumab, 4 Other Products
April 24, 2017
- MHLW Panel OKs 2-Year Extension of Reexamination Period for E Keppra due to Development of Dosage for Children Younger than 4
April 24, 2017
- MHLW to Examine Bayer Issue from Pharmaceutical Law Viewpoint without Prejudgment: Bureau Chief
April 21, 2017
- Lawmakers Whispering Thresholds for Off-Year-Revision Products; Top 30% in Discrepancy Rates Floated
April 21, 2017
- MOF Puts June-End Generic Share at Around 65%, Just Shy of Mid-Year 70% Target
April 21, 2017
- MOF Calls for Scrapping Price Maintenance Premium
April 21, 2017
- MHLW Cautions on Incidences of Multiple Vertebral Body Fractures after Discontinuation of Pralia Treatment
April 21, 2017
- MHLW Re-Cautions Use of Sleep/Anxiolytic/Epilepsy Agents Containing 44 APIs
April 19, 2017
- Optimal Use Guidelines Issued for Opdivo Use in RCC, Hodgkin’s Lymphoma
April 19, 2017
- New MHLW Panel Starts Discussions on Proper Drug Use Guidelines for Elderly; Final Report Expected by End of FY2018
April 19, 2017
- Amicus Takes Over GSK’s Orphan Status for Migalastat for Fabry’s Disease
April 18, 2017
- Review of 14-Day Prescription Limit Up for Chuikyo Discussion Again
April 18, 2017
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…